Pharmacokinetic and pharmacodynamic properties of gs-9620, a novel toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral dosess

Journal of Pharmacology and Experimental Therapeutics

Volumn 348, Issue 1, 2014, Pages 96-105

  Fosdick, Abigail ^a   Zheng, Jim ^b   Pflanz, Stefan ^c   Frey, Christian R ^c   Hesselgesser, Joseph ^d   Halcomb, Randall L ^e   Wolfgang, Grushenka ^a   Tumas, Daniel B ^c  

^a Departments of Drug Safety Evaluation   (United States)

^b Drug Metabolism ^*  (United States)

^c Departments of Biomedical and Chemical Engineering   (United States)

^d Clinical Virology and Medicinal Chemistry   (United States)

^e GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ALPHA INTERFERON; CHEMOKINE; CYTOKINE; GS 9620; INTERFERON; MESSENGER RNA; MYXOVIRUS RESISTANCE PROTEIN; PROTEIN MX1; PROTEIN OAS1; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CYTOKINE PRODUCTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG HALF LIFE; DRUG METABOLISM; DRUG STABILITY; ENZYME INHIBITION; FEMALE; GENE INDUCTION; HUMAN; HUMAN EXPERIMENT; INNATE IMMUNITY; LIVER PARENCHYMA; LOW DRUG DOSE; LYMPHOID TISSUE; MACACA FASCICULARIS; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; NORMAL HUMAN; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS INHIBITION; SINGLE DRUG DOSE; VOLUNTEER;

ADMINISTRATION, ORAL; ANIMALS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; HUMANS; INTERFERON-ALPHA; MACACA FASCICULARIS; MICE; PTERIDINES; TOLL-LIKE RECEPTOR 7;

EID: 84891640554     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.207878     Document Type: Article

References (27)

1. Barbalat R, Ewald SE, Mouchess ML, and Barton GM (2011) Nucleic acid recognition by the innate immune system. Annu Rev Immunol 29:185-214.
2. Colonna M, Trinchieri G, and Liu YJ (2004) Plasmacytoid dendritic cells in immunity. Nat Immunol 5:1219-1226.
3. de Veer MJ, Holko M, Frevel M, Walker E, Der S, Paranjape JM, Silverman RH, and Williams BR (2001) Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol 69:912-920.
4. Edwards AD, Diebold SS, Slack EMC, Tomizawa H, Hemmi H, Kaisho T, Akira S, and Reis e Sousa C (2003) Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8 a1 DC correlates with unresponsiveness to imidazoquinolines. Eur J Immunol 33:827-833.
5. Feld JJ and Hoofnagle JH (2005) Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436:967-972.
6. Gorden KB, Gorski KS, Gibson SJ, Kedl RM, Kieper WC, Qiu X, Tomai MA, Alkan SS, and Vasilakos JP (2005) Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 174:1259-1268.
7. He X, Jia H, Jing Z, and Liu D (2013) Recognition of pathogen-associated nucleic acids by endosomal nucleic acid-sensing toll-like receptors. Acta Biochim Biophys Sin (Shanghai) 45:241-258.
8. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdörfer B, Giese T, Endres S, and Hartmann G (2002) Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 168:4531-4537.
9. Ito T, Amakawa R, Kaisho T, Hemmi H, Tajima K, Uehira K, Ozaki Y, Tomizawa H, Akira S, and Fukuhara S (2002) Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J Exp Med 195:1507-1512.
10. Jarrossay D, Napolitani G, Colonna M, Sallusto F, and Lanzavecchia A (2001) Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol 31:3388-3393.
11. Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F, and Liu YJ (2001) Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 194:863-869.
12. Kanzler H, Barrat FJ, Hessel EM, and Coffman RL (2007) Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 13: 552-559.
13. Ketloy C, Engering A, Srichairatanakul U, Limsalakpetch A, Yongvanitchit K, Pichyangkul S, and Ruxrungtham K (2008) Expression and function of Toll-like receptors on dendritic cells and other antigen presenting cells from non-human primates. Vet Immunol Immunopathol 125:18-30.
14. Lanford RE, Guerra B, Chavez D, Giavendoni L, Hodara VL, Brasky KM, Fosdick A, Frey CR, Zheng J, and Wolfgang G, et al. (2013) GS-9620, an oral agonist of Tolllike receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology 144:1508-1517.
15. Lopatin U, Wolfgang G, Tumas D, Frey CR, Ohmstede C, Hesselgesser J, Kearney B, Moorehead L, Subramanian GM, and McHutchison JG (2013) Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist. Antivir Ther 18:409-418.
16. Marcellin P, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Jin R, Gurel S, Lu ZM, and Wu J, et al. (2009) Sustained response of hepatitis B e antigennegative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 136:2169-2179.
17. Menne S, Tennant BC, Liu KH, Ascenzi MA, Baldwin BH, Bellezza CA, Cote PJ, Zheng X, Wolfgang G, and Tumas D (2011) Anti-viral efficacy and induction of an antibody response against surface antigen with the TLR7 agonist GS-9620 in the woodchuck model of chronic HBV infection. J Hepatol 54 (S1):S441.
18. Moucari R, Korevaar A, Lada O, Martinot-Peignoux M, Boyer N, Mackiewicz V, Dauvergne A, Cardoso AC, Asselah T, and Nicolas-Chanoine MH, et al. (2009) High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol 50:1084-1092.
19. Reijnders JG, Rijckborst V, Sonneveld MJ, Scherbeijn SM, Boucher CA, Hansen BE, and Janssen HL (2011) Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol 54:449-454.
20. Roers A, Hochkeppel HK, Horisberger MA, Hovanessian A, and Haller O (1994) MxA gene expression after live virus vaccination: a sensitive marker for endogenous type I interferon. J Infect Dis 169:807-813.
21. Roethle PA, McFadden RM, Yang H, Hrvatin P, Hui H, Graupe M, Gallagher B, Chao J, Hesselgesser J, and Duatschek P, et al. (2013) Identification and Optimization of Pteridinone Toll-like Receptor 7 (TLR7) Agonists for the Oral Treatment of Viral Hepatitis. J Med Chem 56:7324-7333.
22. Schattner A, Merlin G, Wallach D, Rosenberg H, Bino T, Hahn T, Levin S, and Revel M (1981) Monitoring of interferon therapy by assay of (29-59) oligo-isoadenylate synthetase in human peripheral white blood cells. J Interferon Res 1:587-594.
23. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, and Rice CM (2011) A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472:481-485.
24. Tumas D, Zheng X, Rhodes G, Duatschek P, Hesselgesser J, Frey C, Henne I, Fosdick A, Halcomb R, and Wolfgang G (2011) Preclinical characterization of GS-9620, a potent and selective oral TLR7 agonist. J Hepatol 54:S446-S447.
25. Thomas A, Laxton C, Rodman J, Myangar N, Horscroft N, and Parkinson T (2007) Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection. Antimicrob Agents Chemother 51:2969-2978.
26. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research(2005) Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. http://www.fda.gov/downloads/drugs/ guidancecomplianceregulatoryinformation/guidances/ucm078932.pdf.
27. von Wussow P, Jakschies D, Hochkeppel HK, Fibich C, Penner L, and Deicher H (1990) The human intracellular Mx-homologous protein is specifically induced by type I interferons. Eur J Immunol 20:2015-2019.